Valuation: Supernus Pharmaceuticals, Inc.

Market Cap 2.65B 2.3B 2.14B 1.97B 3.71B 253B 3.78B 25.28B 9.9B 126B 9.94B 9.72B 422B P/E 2026 *
102x
P/E 2027 * 30.5x
Enterprise Value 2.65B 2.3B 2.14B 1.97B 3.71B 253B 3.78B 25.28B 9.9B 126B 9.94B 9.72B 422B EV / Sales 2026 *
3.05x
EV / Sales 2027 * 2.59x
Free-Float
95.54%
Yield 2026 *
-
Yield 2027 * -
1 day-2.06%
1 week-3.35%
Current month-1.94%
1 month-1.94%
3 months-4.98%
6 months-5.29%
Current year-8.23%
1 week 45.5
Extreme 45.5
48.45
1 month 45.5
Extreme 45.5
51.37
Current year 42.45
Extreme 42.45
59.68
1 year 34.64
Extreme 34.64
59.68
3 years 21.99
Extreme 21.99
59.68
5 years 21.99
Extreme 21.99
59.68
10 years 13.12
Extreme 13.12
61.25
Manager TitleAgeSince
Chief Executive Officer 64 21/12/2005
Director of Finance/CFO 67 22/08/2021
Compliance Officer 63 31/12/2011
Director TitleAgeSince
Director/Board Member 64 21/12/2005
Chairman 81 09/08/2016
Director/Board Member 80 15/11/2010
Date Insider Type Main position Quantity % Market Cap.
16/03/26 Fiscal year

Chief Technology Officer

321,750 0.5738%
01/03/26 Other

Responsable ventes & marketing

167,957 0.2995%
28/02/26 Free

Chief Financial Officer

6,000 0.0107%
Change 5-day change 1-year change 3-year change Capi.($)
-2.06%-3.35%+35.91%+49.93% 2.65B
-0.44%-0.53%+58.76%+22.05% 321B
+0.98%+3.77%+30.92%-9.64% 71.5B
+0.02%+3.04%+38.65%+90.79% 9.88B
-3.60%-2.43%-1.64%-5.95% 8.7B
+2.65%+1.04%-23.09%-5.02% 4.25B
+5.26%+5.41%-38.54%+12.12% 3.86B
-3.86%-8.18%-12.14%-2.26% 3.47B
-0.68%+4.52%-4.75%-5.33% 2.23B
-5.33%-12.77%-32.37%+13.32% 1.7B
Average -0.70%+1.03%+5.17%+16.00% 42.88B
Weighted average by Cap. -0.17%+4.42%+49.34%+17.22%

Financials

2026 *2027 *
Net sales 867M 753M 699M 645M 1.22B 82.79B 1.24B 8.28B 3.24B 41.12B 3.26B 3.19B 138B 1.02B 888M 825M 761M 1.43B 97.65B 1.46B 9.77B 3.82B 48.5B 3.84B 3.76B 163B
Net income 25.92M 22.52M 20.91M 19.28M 36.33M 2.47B 36.98M 248M 96.93M 1.23B 97.35M 95.22M 4.13B 92.99M 80.78M 75.01M 69.18M 130M 8.88B 133M 888M 348M 4.41B 349M 342M 14.83B
Net Debt - -
Logo Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
Employees
778
Date Price Change Volume
30/07/26 US$45.61 -2.06% 468,740
29/07/26 US$46.57 -2.43% 522,131
28/07/26 US$47.73 +1.60% 538,195
27/07/26 US$46.98 +1.69% 523,013
24/07/26 US$46.20 -2.10% 521,935
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
45.61USD
Average target price
63.50USD
Spread / Average Target
+39.22%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SUPN Stock